Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(23):1791-1792; doi:10.1093/jnci/dji412
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Altundag, K.
Right arrow Articles by Atik, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Altundag, K.
Right arrow Articles by Atik, M. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

CORRESPONDENCE

Re: Cetuximab Therapy and Symptomatic Hypomagnesemia

Kadri Altundag, Ozden Altundag, Mauricio Z. Baptista, Selahattin Turen, Mustafa A. Atik

Affiliations of authors: Department of Medical Oncology, Institute of Oncology (KA), Department of Internal Medicine, Faculty of Medicine (ST), Hacettepe University, Ankara, Turkey; Department of Medical Oncology, Ankara Numune Hospital, Ankara, Turkey (OA); Department of Clinical Oncology, Hospital Maternidade De Campinas, Campinas, Brazil (MZB); Department of Neurosurgery Baylor College of Medicine, Houston, TX (MAA)

Correspondence to: Kadri Altundag, MD, 8181 Fannin St., No. 728, Houston, TX 77054 (e-mail: drkadri@usa.net).

The first 10% of the full text of this article appears below.

We read with interest the article by Schrag et al. (1) regarding cetuximab and symptomatic hypomagnesemia. They . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?